Advanced carcinoma of the ovary with central nervous system relapse

Ross, Winifred M.; Carmichael, John A.; Shelley, Wendy

doi:10.1016/0090-8258(88)90254-5

Cited by 30 publications

(22 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Larson et al 5 reported that the incidence of CNS metastasis from an ovarian primary at the M.D. Anderson Hospital was only 0.29%, and Ross et al 6 reported a higher incidence, of 2% at the Kingston Regional Cancer Center. Both of these groups indicated that the number of CNS metastases may be increasing because of improved primary control and longer survival of ovarian cancer patients.…”

Section: Discussionmentioning

confidence: 99%

“…A MRI scan with contrast medium before chemotherapy (TPE; see text) showed enhanced metastases in parasagittal meninges and in a localized cortical area in the Silvian fissure. B MRI scan with contrast medium after treatment showed complete disappearance of the meningeal lesion mated that the incidence could be 0.08%-0.28% [2% (CNS metastases) ϫ 4%-14% (proportion of meningeal carcinomatosis in CNS metastases)] of all ovarian carcinomas, on the basis of the recent reviews of Cormio et al 2 and Ross et al 6 Cormio et al 2 described only six patients with meningeal carcinomatosis from ovarian carcinoma in a review of 12 clinical series from the literature. According to our MEDLINE search from 1976 to 1999, only one Japanese 8 and 11 reports from other countries [1][2][3]6,[9][10][11][12][13][14][15] were published related to leptomeningeal carcinomatosis from ovarian carcinoma ( Table 1).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Meningeal carcinomatosis from an ovarian primary with complete response to adjuvant chemotherapy after cranial irradiation

et al. 2001

View full text Add to dashboard Cite

Meningeal metastasis is rare in the clinical course of ovarian carcinoma, and its prognosis is poor. Meningeal dissemination of carcinoma is usually treated by intrathecal administration of methotrexate and total brain irradiation, although these treatments are usually ineffective. We experienced a case of meningeal relapse from ovarian carcinoma resistant to multiple antineoplastic agents in a 64-year-old woman who was treated with eight different chemotherapy regimens after her initial operation 7 years previously. Intrathecal administrations of methotrexate or cisplatin with dexamethasone were not effective. Fifty-Gy whole cranial irradiation inhibited increases in serum carbohydrate antigen (CA) 125 levels and further tumor growth. Adjuvant chemotherapy was required to alleviate frequent headaches and to decrease serum CA125 level and tumor size. Intravenous administration of 45 mg paclitaxel and 35 mg cisplatin, and oral administration of 50 mg etoposide were carried out for 5 days. This treatment was repeated every 3 weeks. After four courses of treatment, meningeal carcinomatosis was not detectable on computed tomography (CT) and magnetic resonance imaging (MRI) scans. The patient's serum levels of CA125 rapidly fell to beneath normal limits and remained normal. She is still alive and clinically free of recurrence 4 months after the last cycle of chemotherapy. As well as reporting our experience with this case, we also present a review of the literature on meningeal carcinomatosis from ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Meningeal carcinomatosis from an ovarian primary with complete response to adjuvant chemotherapy after cranial irradiation

et al. 2001

View full text Add to dashboard Cite

show abstract

“…In 29 series in which the number of ovarian carcinoma patients is available, 34,728 ovarian carcinoma patients were surveyed, and 413 (1.19%) of them were found to have CNS metastases [6, 20–22, 24–27, 29–31, 33–35, 37, 39–43, 45–49, 52–55] (Table 1). The incidence of CNS metastasis among ovarian carcinoma patients was <1% in 5 series [20, 21, 24, 47, 48], 1–1.9% in 10 series [22, 27, 33, 39, 41–43, 49, 54, 55], 2–2.9% in 8 series [6, 29, 31, 34, 35, 45, 46, 53], 3–3.9% in 3 series [37, 40, 52], and ≥4% in 3 series [25, 26, 30] (Table 1). The claim made by some authors that the incidence of brain metastases among ovarian carcinoma patients is rising rapidly and approaching 12% [30] is not supported by most series published in the literature showing that the incidence of brain metastasis among ovarian carcinoma patients is within the range of 1–3% (Table 1).…”

Section: Incidencementioning

confidence: 99%

Brain Metastases from Ovarian Carcinoma

Piura

2011

ISRN Oncology

View full text Add to dashboard Cite

This paper will focus on knowledge related to brain metastases from ovarian carcinoma. So far, less than 600 cases were documented in the literature with an incidence among ovarian carcinoma patients ranging from 0.29% to 11.6%. The ovarian carcinoma was usually an advanced-stage epithelial serous carcinoma, and the median interval between diagnosis of ovarian carcinoma and brain metastases was 2 years. Most often, brain metastases, affected the cerebrum, were multiple and part of a disseminated disease. Treatment of brain metastasis has evolved over the years from whole brain radiotherapy (WBRT) only to multimodal therapy including surgical resection or stereotactic radiosurgery followed by WBRT and/or chemotherapy. The median survival after diagnosis of brain metastases was 6 months; nevertheless, a significantly better survival was achieved with multimodal therapy compared to WBRT only. It is suggested that brain imaging studies should be included in the followup of patients after treatment for ovarian carcinoma.

show abstract

“…Upon neurological examination, however, she was found to have sensory neuropathy in her extremities (which had previously appeared after the postoperative Introduction Metastasis to the central nervous system (CNS) from ovarian carcinoma is uncommon, and leptomeningeal metastasis is even more uncommon. The reported incidence of CNS metastasis from ovarian carcinoma ranges between 0.29% and 4.5%, [1][2][3][4] and the number of reported cases of leptomeningeal metastasis is less than 30.…”

mentioning

confidence: 98%

Leptomeningeal metastasis from ovarian carcinoma successfully treated by the intraventricular administration of methotrexate

Goto

Katsumata

Sasajima³

et al. 2008

Int J Clin Oncol

View full text Add to dashboard Cite

A 60-year-old woman with a history of ovarian carcinoma and complaining of gait instability, dizziness, nausea, and a right temporal headache visited a neurologist. A diagnosis of leptomeningeal metastasis was made, based on the results of a cerebrospinal fluid examination. After the administration of intrathecal methotrexate, her neurological complaints disappeared. An Ommaya intraventricular reservoir was inserted, and methotrexate administration was continued for 11 months, until another recurrence was found in her pelvis. Although uncommon, the possibility of leptomeningeal metastasis from ovarian carcinoma should be considered; in such cases, treatment with intraventricular methotrexate may be effective and feasible and should be considered as a treatment strategy.

show abstract

Advanced carcinoma of the ovary with central nervous system relapse

Cited by 30 publications

References 12 publications

Meningeal carcinomatosis from an ovarian primary with complete response to adjuvant chemotherapy after cranial irradiation

Meningeal carcinomatosis from an ovarian primary with complete response to adjuvant chemotherapy after cranial irradiation

Brain Metastases from Ovarian Carcinoma

Leptomeningeal metastasis from ovarian carcinoma successfully treated by the intraventricular administration of methotrexate

Contact Info

Product

Resources

About